Our Approach

Our Approach

Transforming the treatments of people living with serious and rare diseases

Akcea is focused on addressing the unmet needs and complex medical challenges of patients with important, but less well-understood, serious and rare disorders.

Our investigational treatments are based on Ionis’ proprietary antisense technology. Antisense technology is based on the use of synthetic nucleic acid sequences to interrupt the production of a specified protein by targeting the specific corresponding messenger RNA, or mRNA, that encodes that protein. In this way, antisense drugs can be used to reduce the level of proteins that cause, or contribute to, the progression of various diseases. Learn more about Ionis Pharmaceuticals’ RNA Technology.

Our current pipeline includes drugs with the potential to treat patients with disorders that other technologies, such as small molecules and antibodies, have not been able to adequately address. While traditional drugs modify proteins involved in diseases, the treatments being developed by Akcea decrease the production of these proteins in the first place, offering the potential to significantly improve how serious and rare disorders are addressed.


Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below.

Go to ionispharma.com